×
About 2,069 results

ALLMedicine™ Paroxysmal Nocturnal Hemoglobinuria Center

Research & Reviews  979 results

COVID-19 Vaccines Induce Severe Hemolysis in Paroxysmal Nocturnal Hemoglobinuria.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099541
Blood Gerber GF, Yuan X et. al.

May 4th, 2021 - COVID-19 Vaccines Induce Severe Hemolysis in Paroxysmal Nocturnal Hemoglobinuria.|2021|Gerber GF,Yuan X,Yu J,Cher BAY,Braunstein EM,|

Iron-driven alterations on red blood cell-derived microvesicles amplify coagulation dur...
https://doi.org/10.1055/a-1497-9573
Thrombosis and Haemostasis; Delvasto L, Roem D et. al.

May 3rd, 2021 - Hemolytic disorders characterized by complement-mediated intravascular hemolysis, such as autoimmune hemolytic anemia and paroxysmal nocturnal hemoglobinuria, are often complicated by life-threatening thromboembolic complications. Severe hemolytic...

Predicting response of severe aplastic anemia to immunosuppression combined with eltrom...
https://doi.org/10.3324/haematol.2021.278413
Haematologica Zaimoku Y, Patel BA et. al.

Apr 29th, 2021 - Pretreatment blood counts, particularly the absolute reticulocyte count (ARC) ≥25×109/L, correlate with response to immunosuppressive therapy (IST) in severe aplastic anemia (SAA). In recent trials, eltrombopag (EPAG) combined with standard IST yi...

Efficacy and Safety of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria: A Systematic...
https://doi.org/10.1097/MPH.0000000000002178
Journal of Pediatric Hematology/oncology; Zhou S, Dong X et. al.

Apr 26th, 2021 - Eculizumab is indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). This study aimed to evaluate the efficacy and safety of eculizumab in patients with PNH. PubMed, EMBASE, The Cochrane Library, and ClinicalTrials.gov were sear...

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
https://doi.org/10.1056/NEJMoa2029073
The New England Journal of Medicine; Hillmen P, Szer J et. al.

Mar 17th, 2021 - Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot address extravascular hemolysis. Pegcetacoplan...

see more →

Guidelines  2 results

Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and ...
https://doi.org/10.1002/cyto.b.20525
Cytometry. Part B, Clinical Cytometry; Borowitz MJ, Craig FE et. al.

Jun 9th, 2010 - Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematopoietic stem cell disorder characterized by a somatic mutation in the PIGA gene, leading to a deficiency of proteins linked to the cell membrane via glycophosphatidylinositol (GPI) anchors....

SOLIRIS® (ECULIZUMAB)
https://alexion.com/Products/Soliris

Soliris® is a first-in-class terminal complement inhibitor discovered, developed, and commercialized by Alexion. Soliris® works by inhibiting terminal complement, a part of the immune system that, when activated in an uncontrolled manner, plays a...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  1,017 results

COVID-19 Vaccines Induce Severe Hemolysis in Paroxysmal Nocturnal Hemoglobinuria.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099541
Blood Gerber GF, Yuan X et. al.

May 4th, 2021 - COVID-19 Vaccines Induce Severe Hemolysis in Paroxysmal Nocturnal Hemoglobinuria.|2021|Gerber GF,Yuan X,Yu J,Cher BAY,Braunstein EM,|

Iron-driven alterations on red blood cell-derived microvesicles amplify coagulation dur...
https://doi.org/10.1055/a-1497-9573
Thrombosis and Haemostasis; Delvasto L, Roem D et. al.

May 3rd, 2021 - Hemolytic disorders characterized by complement-mediated intravascular hemolysis, such as autoimmune hemolytic anemia and paroxysmal nocturnal hemoglobinuria, are often complicated by life-threatening thromboembolic complications. Severe hemolytic...

Predicting response of severe aplastic anemia to immunosuppression combined with eltrom...
https://doi.org/10.3324/haematol.2021.278413
Haematologica Zaimoku Y, Patel BA et. al.

Apr 29th, 2021 - Pretreatment blood counts, particularly the absolute reticulocyte count (ARC) ≥25×109/L, correlate with response to immunosuppressive therapy (IST) in severe aplastic anemia (SAA). In recent trials, eltrombopag (EPAG) combined with standard IST yi...

Efficacy and Safety of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria: A Systematic...
https://doi.org/10.1097/MPH.0000000000002178
Journal of Pediatric Hematology/oncology; Zhou S, Dong X et. al.

Apr 26th, 2021 - Eculizumab is indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). This study aimed to evaluate the efficacy and safety of eculizumab in patients with PNH. PubMed, EMBASE, The Cochrane Library, and ClinicalTrials.gov were sear...

Soliris - eculizumab injection, solution, concentrate-Alexion Pharmaceuticals Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722

Apr 19th, 2021 - Soliris is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis (1.1). The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-med...

see more →

News  65 results

Novartis Gets FDA Breakthrough Therapy Tag for Experimental Iptacopan
https://www.medscape.com/viewarticle/942735

Dec 16th, 2020 - ZURICH (Reuters) - Novartis got the U.S. Food and Drug Administration's Breakthrough Therapy tag for its experimental medicine iptacopan, which the Swiss drugmaker hopes wins approval to treat the rare blood disorder paroxysmal nocturnal hemoglobi...

The evolving landscape of complement inhibition therapy
https://www.mdedge.com/fedprac/article/215831/anemia/evolving-landscape-complement-inhibition-therapy?channel=41022
I. Romina Sosa, MD, PhD

Jan 21st, 2020 - The introduction of eculizumab, a monoclonal antibody targeting C5 of the complement cascade, revolutionized the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare hematologic disorder characterized by complement-mediated intravascular.

FDA Clears Ravulizumab for Atypical Hemolytic Uremic Syndrome
https://www.medscape.com/viewarticle/920120

Oct 20th, 2019 - The US Food and Drug Administration (FDA) has approved ravulizumab (Ultomiris, Alexion Pharmaceuticals) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and children age 1 month or older with atypical hemolytic uremic synd...

C3 inhibitor shows potential in PNH and AIHA
https://www.mdedge.com/hematology-oncology/article/199135/anemia/c3-inhibitor-shows-potential-pnh-and-aiha?channel=39313
Will Pass

Apr 18th, 2019 - GLASGOW – APL-2, a complement factor 3 (C3) inhibitor, may be a future treatment option for paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA), according to investigators from two separate studies. Will Pass/MDedge Ne.

FDA approves ravulizumab for PNH
https://www.mdedge.com/hematology-oncology/article/192205/anemia/fda-approves-ravulizumab-pnh
HT Staff

Dec 25th, 2018 - Photo from Business Wire Ravulizumab (Ultomiris) The U. S.

see more →

Patient Education  1 results see all →